DNAprint Genomics (DNAG)

[worktoplay]

Speculation...

Are these related?

DNAPrint Wins FAMRI Research Grant

Thursday February 20, 9:43 am ET

SARASOTA, Fla., Feb. 20 /PRNewswire-FirstCall/ -- DNAPrint (OTC Bulletin Board: DNAP - News; the "Company"), the world leader in the measurement of population structure for disease genetics, personalized medicine and forensics profiling, announced today that it has been awarded part of a 2-year grant worth $200,000 to study population genetic links between cervical disease and Environmental Tobacco Smoke (ETS).

The award was made by the Flight Attendants Medical Research Institute (FAMRI), which was established as part of the $300M tobacco settlement finalized in 1997. The grant, titled "Genetic Susceptibility to Cervical Cancer in Second Hand Smokers", was written in collaboration with the University of Miami School of Medicine to mirror a study the Company and the University executed last year. That study was successful in identifying genetic markers of variable first-line response to paclitaxel/carboplatin chemotherapy, and led to the development of OVANOME, the Company's first chemopredictive product.

The ultimate objective of the funded work is genomics-empowered disease prevention. There is considerable evidence that invasive cervical cancer arises from intraepithelial neoplasia (CIN) and that human papillomavirus (HPV) is involved in this initiation. However, HPV infection alone is clearly insufficient to fully explain CIN, and evidence suggests that ETS exposure is a contributing risk factor. The study funded today will employ DNAPrint's innovative approach for whole-genome screening (ADMIXMAP) to identify gene variants linked to this risk. A successful outcome could lead to a better understanding of the environmental and heritable mechanisms for CIN and, eventually, to the development of new preventative drugs and genomics-based tests.

http://www.leespharm.com/EN/news/news_1875.html

Approval received to initiate clinical study on cervicitis for Yallaferon

(Hong Kong, 7 November 2003) Lee's Pharmaceutical Holdings Limited (GEM Stock: 8221; Website: www.leespharm.com) today announced that the approval was just received from the State Food and Drug Administration of the People's Republic of China to initiate clinical study on cervicitis for its flagship product Raw recombinant human Ï«-2b interferon gel¯ - Yallaferon.

Cervicitis is very common, affecting more than half of all women at some point during their adult lives. Human papillomaviruses (HPV¯) and herpes virus are the most common virus found in cervicitis, which can lead to cervical cancer. If the cervicitis is caused by infection, antibiotics or antiviral medicines may be prescribed. In additions, it is sometimes necessary to destroy the inflamed tissue of the cervix which can be achieved by cryosurgery, electrocauterization and laser therapy. However, the high recurrence rate, vaginal discharge or vaginal bleeding after surgery have made the methods undesirable.........

The reason I ask is:

http://www.prbpharmaceuticals.com/virology/additional.asp

Additional Virology Group Products

Yallaferon

Yallaferon is a proprietary preparation of interferon for topical use developed by and licensed from Lees Pharmaceuticals (HK). Yallaferon is for the treatment of condyloma acuminata (genital warts, being a kind of wart) and other superficial viral infections such as herpes. Yallaferon has successfully completed a 141-patient clinical trial organized by Beijing Medical University The First Hospital in August 1999. Prior to the launch of Yallaferon, the available route of administration on interferon for treatment of viral infection was by way of injection only. However, for diseases, such as genital warts, which is superficial and spot-focused in nature, it is difficult to apply high enough concentration of interferon locally by way of systemic injection without causing signficant side effects. Yallaferon, which is in gel form, can be applied locally and directly to the infection site.

Later,
W2P